Ofir Elalouf1,2, Vinod Chandran3,4,5,6. 1. Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Canada. 2. Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network Toronto, 1E 416, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada. 3. Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network Toronto, 1E 416, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada. vinod.chandran@uhnresearch.ca. 4. Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada. vinod.chandran@uhnresearch.ca. 5. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. vinod.chandran@uhnresearch.ca. 6. Institute of Medical Science, University of Toronto, Toronto, ON, Canada. vinod.chandran@uhnresearch.ca.
Abstract
PURPOSE OF REVIEW: To highlight the recently approved therapeutic agents in psoriatic arthritis (PsA), drugs in the pipeline, as well as to discuss efficacy with regard to different clinical domains of PsA. RECENT FINDINGS: More than 15 years ago, tumor necrosis factor inhibitors (TNFi) were the first biologic disease modifying anti-rheumatic drugs (bDMARDs) that were approved for the treatment of PsA. Since then, multiple new therapeutic agents inhibiting other targets have emerged including biologics targeting interleukin (IL) 12/23, and IL 17 and oral agents targeting phosphodiesterase 4 (PDE4) and Janus kinases (JAKs). Many new agents with various modes of action including selective inhibition of IL 23, therapies promoting activated T cell apoptosis, inhibition of tyrosine kinase 2 (TYK2), and more are under active assessment in ongoing clinical trials. Effective therapies for treating PsA have emerged over the last 15 years and newer agents continue to be discovered, allowing greater therapeutic options for controlling psoriatic disease activity and preventing joint damage and disability. Personalized therapy for patients with PsA is now a possibility.
PURPOSE OF REVIEW: To highlight the recently approved therapeutic agents in psoriatic arthritis (PsA), drugs in the pipeline, as well as to discuss efficacy with regard to different clinical domains of PsA. RECENT FINDINGS: More than 15 years ago, tumornecrosis factor inhibitors (TNFi) were the first biologic disease modifying anti-rheumatic drugs (bDMARDs) that were approved for the treatment of PsA. Since then, multiple new therapeutic agents inhibiting other targets have emerged including biologics targeting interleukin (IL) 12/23, and IL 17 and oral agents targeting phosphodiesterase 4 (PDE4) and Janus kinases (JAKs). Many new agents with various modes of action including selective inhibition of IL 23, therapies promoting activated T cell apoptosis, inhibition of tyrosine kinase 2 (TYK2), and more are under active assessment in ongoing clinical trials. Effective therapies for treating PsA have emerged over the last 15 years and newer agents continue to be discovered, allowing greater therapeutic options for controlling psoriatic disease activity and preventing joint damage and disability. Personalized therapy for patients with PsA is now a possibility.
Authors: Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson Journal: N Engl J Med Date: 2012-08-09 Impact factor: 91.245
Authors: Philip J Mease; Iain B McInnes; Bruce Kirkham; Arthur Kavanaugh; Proton Rahman; Désirée van der Heijde; Robert Landewé; Peter Nash; Luminita Pricop; Jiacheng Yuan; Hanno B Richards; Shephard Mpofu Journal: N Engl J Med Date: 2015-10 Impact factor: 91.245
Authors: A Kavanaugh; J Kremer; L Ponce; R Cseuz; O V Reshetko; M Stanislavchuk; M Greenwald; A Van der Aa; F Vanhoutte; C Tasset; P Harrison Journal: Ann Rheum Dis Date: 2016-12-19 Impact factor: 19.103
Authors: Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis Journal: N Engl J Med Date: 2014-07-09 Impact factor: 91.245
Authors: Maurizio Cutolo; Gary E Myerson; Roy M Fleischmann; Frédéric Lioté; Federico Díaz-González; Filip Van den Bosch; Helena Marzo-Ortega; Eugen Feist; Kamal Shah; ChiaChi Hu; Randall M Stevens; Airi Poder Journal: J Rheumatol Date: 2016-07-15 Impact factor: 4.666
Authors: Amr A Saad; Darren M Ashcroft; Kath D Watson; Kimme L Hyrich; Peter R Noyce; Deborah P M Symmons Journal: Arthritis Res Ther Date: 2009-04-08 Impact factor: 5.156
Authors: Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett Journal: Ann Rheum Dis Date: 2014-03-04 Impact factor: 19.103